Discovery and preclinical development of new antibiotics

References

• CDC. Vital signs: carbapenem-resistant Enterobacteriaceae. MMWR Morb Mortal Wkly Rep. 2013;62:165–70.
   PubMedGoogle Scholar
• Laxminarayan R, Duse A, Wattal C, Zaidi AK, Wertheim HF, Sumpradit N, et al. Antibiotic resistance - the need for global solutions. Lancet Infect Dis. 2013;13:1057–98.
   PubMed Web of Science ®Google Scholar
• Schatz A, Bugie E, Waksman SA. Streptomycin, a substance exhibiting antibiotic activity against gram-positive and gram-negative bacteria. Proc Soc Exp Biol Med. 1944;55:66–9.
   Google Scholar
• Silver LL. Challenges of antibacterial discovery. Clin Microbiol Rev. 2011;24:71–109.
   PubMed Web of Science ®Google Scholar
• Livermore DM; British Society for Antimicrobial Chemotherapy Working Party on The Urgent Need: Regenerating Antibacterial Drug Discovery and Development. Discovery research: the scientific challenge of finding new antibiotics. J Antimicrob Chemother. 2011;66:1941–4.
   PubMed Web of Science ®Google Scholar
• Hughes D. Exploiting genomics, genetics and chemistry to combat antibiotic resistance. Nat Rev Genet. 2003;4:432–41.
   PubMed Web of Science ®Google Scholar
• Seeland S, Torok M, Kettiger H, Treiber A, Hafner M, Huwyler J. A cell-based, multiparametric sensor approach characterises drug-induced cytotoxicity in human liver HepG2 cells. Toxicol In Vitro. 2013;27:1109–20.
   PubMed Web of Science ®Google Scholar
• Volpe DA. Drug-permeability and transporter assays in Caco-2 and MDCK cell lines. Future Med Chem. 2011;3:2063–77.
   PubMed Web of Science ®Google Scholar
• Nettleton DO, Einolf HJ. Assessment of cytochrome p450 enzyme inhibition and inactivation in drug discovery and development. Curr Top Med Chem. 2011;11:382–403.
   Google Scholar
• Staudacher I, Schweizer PA, Katus HA, Thomas D. hERG: protein trafficking and potential for therapy and drug side effects. Curr Opin Drug Discov Devel. 2010;13:23–30.
   Google Scholar
• Farre C, Haythornthwaite A, Haarmann C, Stoelzle S, Kreir M, George M, et al. Port-a-patch and patchliner: high fidelity electrophysiology for secondary screening and safety pharmacology. Comb Chem High Throughput Screen. 2009;12:24–37.
   PubMed Web of Science ®Google Scholar
• Chiba M, Ishii Y, Sugiyama Y. Prediction of hepatic clearance in human from in vitro data for successful drug development. AAPS J. 2009;11:262–76.
   PubMed Web of Science ®Google Scholar
• Nielsen EI, Friberg LE. Pharmacokinetic-pharmacodynamic modeling of antibacterial drugs. Pharmacol Rev. 2013;65:1053–90.
   PubMed Web of Science ®Google Scholar
• Biran A, Yagur-Kroll S, Pedahzur R, Buchinger S, Reifferscheid G, Ben-Yoav H, et al. Bacterial genotoxicity bioreporters. Microb Biotechnol. 2010;3:412–27.
   PubMed Web of Science ®Google Scholar
• Craig WA. Proof of concept: performance testing in models. Clin Microbiol Infect. 2004;10:12–17.
   Google Scholar
• Hughes D, Andersson DI. Selection of resistance at lethal and non-lethal antibiotic concentrations. Curr Opin Microbiol. 2012;15:555–60.
   PubMed Web of Science ®Google Scholar
• Andersson DI, Hughes D. Persistence of antibiotic resistance in bacterial populations. FEMS Microbiol Rev. 2011;35:901–11.
   PubMed Web of Science ®Google Scholar
• Hvidberg H, Struve C, Krogfelt KA, Christensen N, Rasmussen SN, Frimodt-Moller N. Development of a long-term ascending urinary tract infection mouse model for antibiotic treatment studies. Antimicrob Agents Chemother. 2000;44:156–63.
   PubMed Web of Science ®Google Scholar
• Sandberg A, Lemaire S, Van Bambeke F, Tulkens PM, Hughes D, von Eiff C, et al. Intra- and extracellular activities of dicloxacillin and linezolid against a clinical Staphylococcus aureus strain with a small-colony-variant phenotype in an in vitro model of THP-1 macrophages and an in vivo mouse peritonitis model. Antimicrob Agents Chemother. 2011;55:1443–52.
   Google Scholar
• Sandberg A, Hessler JH, Skov RL, Blom J, Frimodt-Moller N. Intracellular activity of antibiotics against Staphylococcus aureus in a mouse peritonitis model. Antimicrob Agents Chemother. 2009;53:1874–83.
   PubMed Web of Science ®Google Scholar
• Andersson DI, Hughes D. Evolution of antibiotic resistance at non-lethal drug concentrations. Drug Resist Updat. 2012;15:162–72.
   PubMed Web of Science ®Google Scholar
• Andersson DI, Hughes D. Antibiotic resistance and its cost: is it possible to reverse resistance? Nat Rev Microbiol. 2010;8:260–71.
   PubMed Web of Science ®Google Scholar
• Coates AR, Halls G. Antibiotics in phase II and III clinical trials. Handb Exp Pharmacol. 2012;211:167–83.
   Google Scholar
• Hernandez V, Crepin T, Palencia A, Cusack S, Akama T, Baker SJ, et al. Discovery of a novel class of boron-based antibacterials with activity against gram-negative bacteria. Antimicrob Agents Chemother. 2013;57:1394–403.
   PubMed Web of Science ®Google Scholar